These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1617 related articles for article (PubMed ID: 25865047)

  • 1. Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.
    Hayashi Y; Bardsley MR; Toyomasu Y; Milosavljevic S; Gajdos GB; Choi KM; Reid-Lombardo KM; Kendrick ML; Bingener-Casey J; Tang CM; Sicklick JK; Gibbons SJ; Farrugia G; Taguchi T; Gupta A; Rubin BP; Fletcher JA; Ramachandran A; Ordog T
    Gastroenterology; 2015 Aug; 149(2):420-32.e16. PubMed ID: 25865047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors.
    Bardsley MR; Horváth VJ; Asuzu DT; Lorincz A; Redelman D; Hayashi Y; Popko LN; Young DL; Lomberk GA; Urrutia RA; Farrugia G; Rubin BP; Ordog T
    Gastroenterology; 2010 Sep; 139(3):942-52. PubMed ID: 20621681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours.
    Chi P; Chen Y; Zhang L; Guo X; Wongvipat J; Shamu T; Fletcher JA; Dewell S; Maki RG; Zheng D; Antonescu CR; Allis CD; Sawyers CL
    Nature; 2010 Oct; 467(7317):849-53. PubMed ID: 20927104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression.
    Tang CM; Lee TE; Syed SA; Burgoyne AM; Leonard SY; Gao F; Chan JC; Shi E; Chmielecki J; Morosini D; Wang K; Ross JS; Kendrick ML; Bardsley MR; Siena M; Mao J; Harismendy O; Ordog T; Sicklick JK
    Oncotarget; 2016 Nov; 7(48):78226-78241. PubMed ID: 27793025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathology of gastrointestinal stromal tumors.
    Hirota S; Isozaki K
    Pathol Int; 2006 Jan; 56(1):1-9. PubMed ID: 16398673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.
    Heinrich MC; Griffith D; McKinley A; Patterson J; Presnell A; Ramachandran A; Debiec-Rychter M
    Clin Cancer Res; 2012 Aug; 18(16):4375-84. PubMed ID: 22745105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
    Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
    Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance.
    Zhu MJ; Ou WB; Fletcher CD; Cohen PS; Demetri GD; Fletcher JA
    Oncogene; 2007 Sep; 26(44):6386-95. PubMed ID: 17452978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression of the IGF pathway family distinguishes subsets of gastrointestinal stromal tumors wild type for KIT and PDGFRA.
    Beadling C; Patterson J; Justusson E; Nelson D; Pantaleo MA; Hornick JL; Chacón M; Corless CL; Heinrich MC
    Cancer Med; 2013 Feb; 2(1):21-31. PubMed ID: 24133624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
    Debiec-Rychter M; Cools J; Dumez H; Sciot R; Stul M; Mentens N; Vranckx H; Wasag B; Prenen H; Roesel J; Hagemeijer A; Van Oosterom A; Marynen P
    Gastroenterology; 2005 Feb; 128(2):270-9. PubMed ID: 15685537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrointestinal stromal tumors.
    Antonescu C
    Curr Top Microbiol Immunol; 2012; 355():41-57. PubMed ID: 22015552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivation of Patched1 in mice leads to development of gastrointestinal stromal-like tumors that express Pdgfrα but not kit.
    Pelczar P; Zibat A; van Dop WA; Heijmans J; Bleckmann A; Gruber W; Nitzki F; Uhmann A; Guijarro MV; Hernando E; Dittmann K; Wienands J; Dressel R; Wojnowski L; Binder C; Taguchi T; Beissbarth T; Hogendoorn PC; Antonescu CR; Rubin BP; Schulz-Schaeffer W; Aberger F; van den Brink GR; Hahn H
    Gastroenterology; 2013 Jan; 144(1):134-144.e6. PubMed ID: 23041331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cas-L was overexpressed in imatinib-resistant gastrointestinal stromal tumor cells.
    Thao le B; Vu HA; Yasuda K; Taniguchi S; Yagasaki F; Taguchi T; Watanabe T; Sato Y
    Cancer Biol Ther; 2009 Apr; 8(8):683-8. PubMed ID: 19417561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs).
    Lasota J; Miettinen M
    Semin Diagn Pathol; 2006 May; 23(2):91-102. PubMed ID: 17193822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth.
    Ran L; Sirota I; Cao Z; Murphy D; Chen Y; Shukla S; Xie Y; Kaufmann MC; Gao D; Zhu S; Rossi F; Wongvipat J; Taguchi T; Tap WD; Mellinghoff IK; Besmer P; Antonescu CR; Chen Y; Chi P
    Cancer Discov; 2015 Mar; 5(3):304-15. PubMed ID: 25572173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors.
    Janeway KA; Liegl B; Harlow A; Le C; Perez-Atayde A; Kozakewich H; Corless CL; Heinrich MC; Fletcher JA
    Cancer Res; 2007 Oct; 67(19):9084-8. PubMed ID: 17909012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.
    Lee JH; Kim Y; Choi JW; Kim YS
    J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High expression of the RNA-binding protein RBPMS2 in gastrointestinal stromal tumors.
    Hapkova I; Skarda J; Rouleau C; Thys A; Notarnicola C; Janikova M; Bernex F; Rypka M; Vanderwinden JM; Faure S; Vesely J; de Santa Barbara P
    Exp Mol Pathol; 2013 Apr; 94(2):314-21. PubMed ID: 23295309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
    Heinrich MC; Corless CL; Demetri GD; Blanke CD; von Mehren M; Joensuu H; McGreevey LS; Chen CJ; Van den Abbeele AD; Druker BJ; Kiese B; Eisenberg B; Roberts PJ; Singer S; Fletcher CD; Silberman S; Dimitrijevic S; Fletcher JA
    J Clin Oncol; 2003 Dec; 21(23):4342-9. PubMed ID: 14645423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 81.